Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen’s Bavarian Nordic in a $225 million deal. The vaccine is aimed at older and/or immunocompromised adults.